Related Experiment Video
Updated: Apr 9, 2026
06:45
Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
Published on: October 4, 2021
3.7K
Droxidopa in neurogenic orthostatic hypotension
Horacio Kaufmann1, Lucy Norcliffe-Kaufmann, Jose-Alberto Palma
1Department of Neurology, New York University School of Medicine, New York, NY, USA.
Expert Review of Cardiovascular Therapy
|June 21, 2015
Summary
Neurogenic orthostatic hypotension (nOH) is a blood pressure condition. Droxidopa, a new treatment, converts to norepinephrine to increase vascular tone and improve symptoms in patients with nOH.
Area of Science:
- Neurology
- Pharmacology
- Cardiovascular Medicine
Background:
- Neurogenic orthostatic hypotension (nOH) involves a drop in blood pressure upon standing, linked to decreased norepinephrine release.
- nOH is associated with neurological conditions like Parkinson disease (PD) and multiple system atrophy (MSA).
Purpose of the Study:
- To summarize the pharmacological profile, mechanism of action, and clinical trial outcomes of droxidopa for nOH treatment.
Main Methods:
- Review of droxidopa's properties as a synthetic amino acid precursor to norepinephrine.
- Analysis of clinical trial data on droxidopa's efficacy and safety in treating nOH.
Main Results:
- Droxidopa is converted to norepinephrine, potentially increasing vascular tone at the neurovascular junction.
- Clinical trials evaluated the efficacy and safety of droxidopa for short-term nOH management.
Conclusions:
- Droxidopa is a recently FDA-approved treatment for short-term management of nOH.
- The drug's mechanism involves conversion to norepinephrine to address the underlying pathophysiology of nOH.
Related Concept Videos
01:24Parkinson's Disease: Treatment
1.4K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.4K
01:23Antihypertensive Drugs: Vasodilators
2.5K
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
2.5K
01:28Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
1.8K
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
1.8K
01:29Drugs Affecting Neurotransmitter Synthesis
2.6K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
2.6K
01:11Direct-Acting Cholinergic Agonists: Therapeutic Uses
2.1K
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
2.1K
01:26Cholinergic Antagonists: Therapeutic Uses
1.7K
Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
1.7K